15 results about "B-Cell Maturation Antigen" patented technology

The disclosure concerns a method of treating cancer, especially, such as multiple myeloma, involving the combination of an anti-BCMA (B cell maturation antigen) antibody, Belantamab mafodotin -GSK2857916- and a gamma-secretase inhibitor, e.g., nirogacestat -PF03084014-. The disclosure also relates to dosages, duration of treatment and time lapses between administration of the anti-BCMA antibody and the gamma-secretase inhibitor.

This provides a multispecific antibody that binds to BCMA. [Solution] A multispecific human heavy chain antibody (e.g., UniAb) that binds to B cell maturation antigen (BCMA). TM Disclosed are methods for producing such antibodies, compositions comprising pharmaceutical compositions containing such antibodies, and their use for treating disorders characterized by BCMA expression. In one embodiment, a multispecific antibody that binds to BCMA is provided, comprising a first binding unit comprising a variable region comprising a CDR3 sequence having at least 85% sequence identity with a specific sequence.

This invention relates to GPRC5D and BCMA-specific chimeric antigen receptors (CARs), specifically providing CARs containing an extracellular antigen-binding domain that binds to a G protein-coupled receptor class C5 group D member (GPRC5D) and B cell maturation antigen (BCMA). The invention also relates to genetically engineered cells expressing such CARs and their use in adoptive cell therapy.

Antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor are disclosed. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Compositions and methods described herein relate to chimeric antigen receptors (CARs) targeting B cell maturation antigen (BCMA) and uses thereof in therapy. Engineered T cells comprising an anti-BCMA CAR are also provided. The engineered cells may comprise a genetic modification in one or more of the HLA-A, HLA-B, TRAC, CIITA, or TGFBR2 genes.

The present disclosure is based at least in part on the discovery of novel BCMA antibodies or antigen-binding fragments thereof, and generally, genetically modified cells (e.g., iNKT cells, CAR T cells, etc.) expressing chimeric antigen receptors comprising anti-BCMA antibodies or antigen-binding fragments thereof exhibit improved properties, including increased binding to BCMA, killing of BCMA-expressing cancer cells in vitro and in vivo, and enhanced persistence in treated subjects.

This disclosure provides a method for treating a subject with cancer or light chain amyloidosis, the method comprising administering to the subject a combination therapy containing an effective amount of nirostat dihydrobromide form A and B cell maturation antigen (BCMA) targeted therapy and providing the use of the combination therapy.

The present invention relates to novel humanized antibodies that bind to the B cell maturation antigen (BCMA), and to immunostimulatory antigen binding molecules comprising these BCMA antibodies, in particular to antigen binding molecules comprising a 4-1BBL trimer that target BCMA; processes for their production; and their use in the treatment of cancer.

Provided are CAR-T cells targeting BCMA and CD19. Specifically, provided is a parallel expression structure for chimeric antigen receptors (CARs) for B cell maturation antigen (BCMA) and a CD19 antigen molecules, and optimizes a CD28 costimulatory domain motif. Further provided is a use of the chimeric antigen receptors for adoptive T cell therapy for B cell-related conditions.

The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.

The present disclosure provides compositions and methods for inhibiting or preventing an immune response to an immunogen (e.g., an immunogenic delivery vehicle) in a subject in need thereof, comprising administering to the subject an effective amount of a plasma cell depleting agent, e.g., an antigen-binding molecule that binds to B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (e.g., an anti-BCMAxCD3 bispecific antibody, or a functional fragment thereof) or a B cell depleting agent, e.g., an antigen-binding molecule that binds to CD20 and CD3 (e.g., an anti-CD20xCD3 bispecific antibody, or a functional fragment thereof), either alone or in combination with one another, and / or in combination with an immunoglobulin depleting agent such as a neonatal fragment crystallizable (Fc) receptor (FcRn) blocker (e.g., efgartigimod).

This invention relates to CAR-T cells targeting BCMA and CD19. Specifically, the invention provides a structure for the parallel expression of a chimeric antigen receptor (CAR) that simultaneously targets B cell maturation antigen (BCMA) and CD19 antigen molecules, and optimizes the motif of the co-stimulatory domain CD28. The invention further provides applications of the chimeric antigen receptor for adoptive T cell therapy for B cell-related conditions.

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

This document provides chimeric antigen receptors (CARs) and CAR-NK cells targeting BCMA and GPRC5D, and their use in the treatment of multiple myeloma (MM). Specifically, this disclosure relates to bispecific CARs, the corresponding encoding polynucleotides of the CARs, and vectors containing the polynucleotides, said CARs comprising: (a) a B cell maturation antigen (BCMA) targeting domain; and (b) a G protein-coupled receptor C family 5 member D (GPRC5D) targeting domain, preferably armed with IL-15, etc. Furthermore, this document also provides CAR-NK cells modified with one or more CARs, and the use of CARs and CAR-NK cells in the treatment of MM.

This disclosure relates to compositions and methods for treating disease using chimeric antigen receptor cells and / or antigen binding domains targeting BCMA.